Orbimed Advisors LLC Keros Therapeutics, Inc. Transaction History
Orbimed Advisors LLC
- $4.15 Billion
- Q2 2024
A detailed history of Orbimed Advisors LLC transactions in Keros Therapeutics, Inc. stock. As of the latest transaction made, Orbimed Advisors LLC holds 1,268,734 shares of KROS stock, worth $75.7 Million. This represents 1.4% of its overall portfolio holdings.
Number of Shares
1,268,734
Previous 1,268,734
-0.0%
Holding current value
$75.7 Million
Previous $84 Million
30.97%
% of portfolio
1.4%
Previous 1.89%
Shares
3 transactions
Others Institutions Holding KROS
# of Institutions
157Shares Held
27.5MCall Options Held
28.7KPut Options Held
1.8K-
Black Rock Inc. New York, NY2.51MShares$150 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.76MShares$105 Million0.0% of portfolio
-
Alkeon Capital Management LLC New York, NY1.6MShares$95.4 Million0.12% of portfolio
-
Darwin Global Management, Ltd. St. Helier, Y91.53MShares$91 Million8.43% of portfolio
-
State Street Corp Boston, MA1.22MShares$72.8 Million0.0% of portfolio
About Keros Therapeutics, Inc.
- Ticker KROS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 25,757,000
- Market Cap $1.54B
- Description
- Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed ...